unknown
Stage
1
Investors
About
Abgentis develops a new broad-spectrum intravenous and oral antibacterial treatment targeting acute, chronic, life-threatening, and drug-resistant infections by optimizing DNA supercoiling inhibitors for enhanced efficacy and low resistance.
Explore Abgentis's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.